Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.

Pérez-Belmonte LM, Sanz-Cánovas J, García de Lucas MD, Ricci M, Avilés-Bueno B, Cobos-Palacios L, Pérez-Velasco MA, López-Sampalo A, Bernal-López MR, Jansen-Chaparro S, Miramontes-González JP, Gómez-Huelgas R

Frontiers in endocrinology24 Jun 2022Cited by 23 (Europe PMC)

PMID35813629PMCIDPMC9263111DOI10.3389/fendo.2022.851035PepBankPUB-35813629

Download PDF PubMedAsk about this study

Jump to 10 results

Summary

BackgroundThe impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure.MethodsIn this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.ResultsA total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01), a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01), and a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01). Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined. Additionally, significant reductions in glycated hemoglobin (-1.4%) and body weight (-12.7 kilograms) were observed as well as a de-intensification of antidiabetic therapy. Moreover, semaglutide was safe and well-tolerated.ConclusionIn obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, the Kansas City Cardiomyopathy Questionnaire total symptom score rose from baseline to 12 months of semaglutide.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, heart failure symptom scores improved over 12 months of semaglutide.
Peptide
Semaglutide
Outcome
IncreaseKansas City Cardiomyopathy Questionnaire total symptom score
Study
n = 136
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
KCCQ total symptom score
59 points
baseline
KCCQ total symptom score
79.9 points
12 months
Source sentences
Summary
there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p<0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362901
02HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, the share of patients in New York Heart Association class III fell from 40.4% to 16.2% over 12 months of semaglutide.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, fewer patients had severe heart failure symptoms after 12 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseProportion of patients in NYHA functional class III
Study
n = 136
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
NYHA class III proportion
40.4%
baseline
NYHA class III proportion
16.2%
12 months
Source sentences
Summary
a reduction in the proportion of patients with New York Heart Association functional class III (40.4% to 16.2%, p<0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362902
03HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, N-terminal pro-brain natriuretic peptide levels fell from baseline to 12 months of semaglutide.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, a blood marker of heart strain fell over 12 months of semaglutide.
Peptide
Semaglutide
Outcome
DecreaseNT-proBNP level
Study
n = 136
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
NT-proBNP
969.5 pg/mL
baseline
NT-proBNP
577.4 pg/mL
12 months
Source sentences
Summary
a reduction in N-terminal pro-brain natriuretic peptide levels (969.5 ± 653.5 vs 577.4 ± 322.1 pg/mL, p<0.01)
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362903
04HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, emergency department visits due to heart failure declined during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, emergency visits for heart failure became less frequent during semaglutide treatment.
Peptide
Semaglutide
Outcome
DecreaseEmergency department visits due to heart failure
Study
n = 136
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined.
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362904
05HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, hospitalizations due to heart failure declined during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, hospital stays for heart failure became less frequent during semaglutide treatment.
Peptide
Semaglutide
Outcome
DecreaseHospitalizations due to heart failure
Study
n = 136
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined.
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362905
06HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, all-cause hospitalizations declined during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, hospital stays for any cause became less frequent during semaglutide treatment.
Peptide
Semaglutide
Outcome
DecreaseAll-cause hospitalizations
Study
n = 136
Outcome group
Cardiovascular events · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Emergency department visits due to heart failure, hospitalizations due to heart failure, and all-cause hospitalizations also declined.
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362906
07HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, glycated hemoglobin fell by 1.4% with semaglutide.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, semaglutide was followed by lower long-term blood sugar.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change
Study
n = 136
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
HbA1c change
−1.4%
12 months
Source sentences
Summary
significant reductions in glycated hemoglobin (-1.4%)
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362907
08HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, body weight fell by 12.7 kg with semaglutide.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, semaglutide was followed by lower body weight.
Peptide
Semaglutide
Outcome
DecreaseBody weight change
Study
n = 136
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Measurements
Body weight change
−12.7 kg
12 months
Source sentences
Summary
body weight (-12.7 kilograms)
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362908
09HumanObservational studyEfficacy outcome
In obese adults with type 2 diabetes and heart failure, antidiabetic therapy was de-intensified during semaglutide treatment.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, patients needed less other diabetes treatment during semaglutide treatment.
Peptide
Semaglutide
Outcome
DecreaseIntensity of antidiabetic therapy
Study
n = 136
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
a de-intensification of antidiabetic therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362909
10HumanObservational studySafety outcome
In obese adults with type 2 diabetes and heart failure, semaglutide was reported as safe and well tolerated.
In plain wordsIn adults with type 2 diabetes, obesity and heart failure, the study reported semaglutide as safe and well tolerated.
Peptide
Semaglutide
Outcome
Not applicableSafety and tolerability
Study
n = 136
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 12 monthsAs given in this study (human).
Source sentences
Summary
Moreover, semaglutide was safe and well-tolerated.
2 context sentences(design, population, supporting numbers)
Summary · context
In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months.
Summary · context
A total of 136 patients were included.
Show in the study text Report a problemFND-3581362910

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.